HALT Study for an Drug to Treat Heart Disease in Cats


Share

Feline hypertrophic cardiomyopathy (HCM) is a heart disease which there is currently no effective treatment, but this may change soon. And this is indeed a game changer for cats, as HCM is likely the number cause of death in adult cats ages around two to ten (before kidney disease and cancers begin to happen).

TriviumVet says, “We are happy to report that after extensive consultation with the Food and Drug Administration (FDA) TriviumVet have been granted concurrence on the HALT Studydesign which allows the study to comment recruitment eligible cats.”

The HALT study is a pivotal placebo-controlled study to determine the effectiveness of TRIV202 in managing left ventricular hypertrophy associated with feline subclinical Hypertrophic Cardiomyopathy (HCM) over 12 months. Here’s the published Scientific Reports study.

Cardiac veterinarians are optimistic about what’s happening now – a game changer for sure.

HALT Study Details

What Cats are Eligible to Participate in the HALT Study? As for any clinical study, there is a detailed list of inclusion and exclusion criteria to ensure that the HALT study findings are valid and robust, and that the safety and welfare of the participating cats are protected. Male, and surgically spayed female, cats with an echocardiography-confirmed diagnosis of subclinical HCM (i.e. that do not yet have outward symptoms of their heart disease) may be eligible if they meet these additional criteria: • Body weight ≥2.5 kg (5.5 lb) • Age 18 months to under 15 years at enrollment.

The cat must be willing to take oral medications.

Elevation of cardiac biomarkers (NTproBNP) – to be confirmed by blood sample at the HALT study clinical site.  Otherwise healthy; e.g. non-diabetic, no chronic infections for participating cats.  Their owner provides consent after being informed of the risks and benefits of participation in the study

Taking part in a clinical study like HALT is a commitment. In addition to the first (screening) visit, you will return to the clinic with your cat for follow-up evaluations five times over the course of the following year. You will also return to the clinic in the days following the screening visit to collect the first supply of study drug; however, your cat does not need to accompany you for this visit. You must continue to dose your cat with the study medication, as well as any other medications deemed necessary by your Study Veterinarian, for the one-year course of the study. It is essential that owners registering for HALT can meet these requirements.

There are no costs to you for participating in this study. All study related activities (physical exams, blood work, urinalysis, Echocardiography, ECGs, etc…) will be provided at no expense. Compensation for travel to the clinic for required visits will not be provided, however at the completion of the study and given all protocol related instructions are followed correctly, participants will be compensated $500.

The HALT Study is not offered everywhere; details are here.

Understanding HCM

For over two decades, via the Ricky Fund, the EveryCat Health Foundation (formerly Winn Feline Foundation) has been supporting studies to better understand HCM, and to attempt to find a treatment. Representatives from Trivium and cardiac veterinarians have expressed gratitude that these studies have made it possible to advance to the point of what will hopefully be an effective treatment but this still requires further evidence.